Denis Katz Clinical Consultant
CNS disorders are now being redefined through molecular signatures, circuit-level dysfunction, and digital phenotypes. This is not a technological evolution it is a structural reset of how drugs are developed, evaluated, and approved.
https://salienceclinical.com/
CNS disorders are now being redefined through molecular signatures, circuit-level dysfunction, and digital phenotypes. This is not a technological evolution it is a structural reset of how drugs are developed, evaluated, and approved.
https://salienceclinical.com/
Denis Katz Clinical Consultant
CNS disorders are now being redefined through molecular signatures, circuit-level dysfunction, and digital phenotypes. This is not a technological evolution it is a structural reset of how drugs are developed, evaluated, and approved.
https://salienceclinical.com/